Elizabeth Dowling

New research reveals how ezogabine targets potassium channels in the brain, offering innovative treatment options for major depressive disorder symptoms.

"Our findings provide a mechanistic explanation for the well-known variations in individual responses to drugs and suggest that subjective beliefs could be a direct target for the treatment of substance use disorders," said Xiaosi Gu, PhD, senior author of the study.

Researchers identified 298 genetic regions linked to bipolar disorder risk in the largest study of its kind.